Who
Tina M. Albertson
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Caribou Biosciences; Chief Medical Officer, Lyell Immunopharma.
In numbers
- Trades disclosed
- 10
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $4,179
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 24 Feb 2023
- Last trade
- 24 Feb 2026
- Last filed
- 24 Feb 2026
Companies traded
Activity over time
1 Feb – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Feb 2026filed 24 Feb 2026 | CRBU Caribou BiosciencesBiotechnology | SEC FORM 4 Sold | $2,0891,066 at $1.96 | filing |
| 24 Feb 2026filed 24 Feb 2026 | CRBU Caribou BiosciencesBiotechnology | SEC FORM 4 Sold | $2,0891,066 at $1.96 | filing |
| 20 Feb 2026filed 24 Feb 2026 | CRBU Caribou BiosciencesBiotechnology | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 20 Feb 2026filed 24 Feb 2026 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —247,500 at $0.00 | filing |
| 20 Feb 2026filed 24 Feb 2026 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —247,500 at $0.00 | filing |
| 20 Feb 2026filed 24 Feb 2026 | CRBU Caribou BiosciencesBiotechnology | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 20 Feb 2025filed 21 Feb 2025 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —66,137 at $0.00 | filing |
| 20 Feb 2025filed 21 Feb 2025 | CRBU Caribou BiosciencesBiotechnology | SEC FORM 4 Code A | —14,589 at $0.00 | filing |
| 19 Aug 2024filed 20 Aug 2024 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 24 Feb 2023filed 28 Feb 2023 | LYEL Lyell Immunopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —700,000 at $0.00 | filing |
News
Caribou Biosciences, Inc. (NASDAQ:CRBU) Stock Has Average Price Target of $5.50CRBU · dailypolitical.com · 19 Oct 2026Head to Head Analysis: Caribou Biosciences (NASDAQ:CRBU) & Vertex Pharmaceuticals (NASDAQ:VRTX)CRBU · tickerreport.com · 14 Oct 2026Caribou Biosciences Halts Off-the-Shelf CRISPR CAR-T Programs for Lymphoma and Myeloma After Failing to Fund Phase 3 TrialCRBU · medicaldaily.com · 10 Oct 2026
0 headlines in the last 90 days name Tina M. Albertson; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.